Research
Metabolic adaptation
Weight gain among persons with HIV on contemporary antiretroviral therapy can lead to overweight/obesity in the first 1 to 2 years, resulting in enhanced cardiometabolic risk.
Healthcare providers should monitor weight changes in persons with HIV on ART to mitigate cardiometabolic risks.
StrongSupportsmedium confidence
Weight gain among persons with HIV PWH) on contemporary antiretroviral therapy (ART) can extend beyond an initial return-to-health phenomenon and lead to overweight/obesity in the first 1 to 2 years, resulting in enhanced cardiometabolic risk.
Why this rating
The claim is based on a review of existing studies.
Source
Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.
Teressa S Thomas et al. · PubMed · 2024
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →